Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A PhaseⅠStudy of HS-10381 in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05378178
Recruitment Status : Not yet recruiting
First Posted : May 18, 2022
Last Update Posted : May 18, 2022
Sponsor:
Information provided by (Responsible Party):
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Brief Summary:
HS-10381 is a small molecular, oral potent, SHP2 inhibitor. The first-in-human trial is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-10381 in Patients With Advanced Solid Tumors.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumor Drug: HS-10381 Phase 1

Detailed Description:
This is a Phase 1 open-label, multicenter study to evaluate the safety, tolerability, PK and preliminary efficacy of HS-10381 in patients with advanced solid tumors by using a "3+3" dose escalation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 51 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-10381 in Patients With Advanced Solid Tumors
Estimated Study Start Date : May 10, 2022
Estimated Primary Completion Date : December 31, 2023
Estimated Study Completion Date : December 31, 2024

Arm Intervention/treatment
Experimental: Phase I:Dose escalation
HS-10381 given orally QD of various dose strengths administered in 21 day dosing cycles.
Drug: HS-10381
Each subject will receive a single dose(C0) of HS-10381 and then repeat doses(C1, C2…) for 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.




Primary Outcome Measures :
  1. Maximum Tolerated Dose of HS-10381 [ Time Frame: 4 weeks after initiation of treatment ]
    To determine the MTD of HS-10381 in subjects with advanced solid tumors.


Secondary Outcome Measures :
  1. Incidence and severity of treatment-emergent adverse events [ Time Frame: Baseline through study completion(28 days after last dose) ]
    The CTCAE criteria will be used to assess adverse events on this trial.

  2. Observed maximum plasma concentration (Cmax) after single dose of HS-10381 [ Time Frame: From pre-dose to 120 hours after single dose on Cycle 0 Day 1. ]
    Cmax will be obtained after single dose of HS-10381 on Cycle 0 Day 1.

  3. Observed maximum plasma concentration (Cmax ss) after multiple dose of HS-10381 [ Time Frame: From pre-dose to 24 hours after the dose on Cycle 2 Day 1 ]
    Cmax ss will be obtained on Cycle 2 Day 1.

  4. Apparent terminal half-life (t1/2) after single dose of HS-10381 [ Time Frame: From pre-dose to 120 hours after single dose on Cycle 0 Day 1 ]
    Apparent terminal half-life is the time measured for the concentration to decrease by one half.

  5. Area under plasma concentration versus time curve from zero to the 24-hour sampling time (AUC0-24) after single dose of HS-10381 [ Time Frame: From pre-dose to 24 hours after single dose on Cycle 0 Day 1 ]
    Area under the plasma concentration versus time curve from time zero to the 24-hour sampling time at which the concentration was at or above the lower limit of quantification (LLQ).

  6. Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) after single dose of HS-10381 [ Time Frame: From pre-dose to 120 hours after single dose on Cycle 0 Day 1 ]
    Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ).

  7. Area under the plasma concentration versus time curve from time zero to infinity (AUC0-∞) after single dose of HS-10381 [ Time Frame: From pre-dose to 120 hours after single dose on Cycle 0 Day 1 ]
    AUC0-∞ was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the LLQ and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

  8. To further evaluation of the anti-tumor activity of HS-10381 by assessment of objective response rate (ORR) [ Time Frame: From the date of first occurrence of complete response (CR) or partial response (PR) on 2 consecutive occasions (≥4 weeks), until the date of disease progression or withdrawal from study,up to 2 years ]
    Anti-tumor efficacy will be assessed by best radiographic response based on Response Evaluation Criteria in Solid Tumors at baseline (Day -28 to -1). For patients that continue on repeating 21-Day cycles after the primary evaluation period, progression will be assessed after each 6 weeks of therapy. ORR is defined as the percentage of patients with a complete response (CR) or partial response (PR) that was confirmed at a subsequent scan at least 4 weeks later, as assessed according to RECIST version 1.1.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men or women aged more than or equal to (≥) 18 years
  2. Advanced solid tumor patients confirmed by histology or cytology for who that standard treatment is invalid, unavailable or intolerable
  3. Patients have at least one target lesion according to RECEST 1.1. The requirements for target lesions are: measurable lesions without local treatment such as irradiation, or with definite progress after local treatment, with the longest diameter ≥ 10 mm in the baseline period (in case of lymph nodes, the shortest axis ≥ 15 mm is required)
  4. ECOG performance status was 0-1 and did not deteriorate in the previous 2 weeks
  5. Estimated life expectancy greater than (>) 12 weeks
  6. Females should be using adequate contraceptive measures throughout the study; should not be breastfeeding at the time of screening, during the study and until 3 months after completion of the study; and must have evidence of non-childbearing potential
  7. Sign Informed Consent Form

Exclusion Criteria:

  1. Treatment with any of the following:

    1. Previous or current treatment with drugs targeting SHP2
    2. Any cytotoxic chemotherapy, investigational agents or anticancer drugs within 28 days of the first dose of study drug
    3. Radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study drug, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks of the first dose.
    4. Major surgery (including craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks of the first dose of study drug.
    5. Known and untreated, or active central nervous system metastases.
  2. Existing abnormal CTCAE≥grade 2 resulted from previous treatment
  3. History of other malignancy
  4. Inadequate bone marrow reserve or organ function
  5. Evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV), unless the hepatitis is considered to be cured, Known history of HIV
  6. History of hypersensitivity to any active or inactive ingredient of HS-10381.
  7. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
  8. Any disease or condition that, in the opinion of the investigator, would compromise the safety of the patient or interfere with study assessments.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05378178


Contacts
Layout table for location contacts
Contact: You Lu, PhD 18980601763 radyoulu@hotmail.com

Locations
Layout table for location information
China, Sichuan
West China Hospital of Sichuan University
Xi'an, Sichuan, China, 610044
Contact: You Lu, PhD    18980601763    radyoulu@hotmail.com   
Sponsors and Collaborators
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: You Lu West China Hospital
Layout table for additonal information
Responsible Party: Jiangsu Hansoh Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier: NCT05378178    
Other Study ID Numbers: HS-10381-101
First Posted: May 18, 2022    Key Record Dates
Last Update Posted: May 18, 2022
Last Verified: April 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jiangsu Hansoh Pharmaceutical Co., Ltd.:
HS-10381
SHP2
Advanced Solid Tumor
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms